<DOC>
	<DOCNO>NCT01001962</DOCNO>
	<brief_summary>Objectives : Primary 1 . Primary prevention new onset hypertension Secondary 1 . Reduction 24h BP type II diabetic prehypertension 2 . Reduction non dip status , day nighttime BP , morning BP surge subject receive EMPAGLIFLOZIN 3 . Reduction total cardiovascular risk 4 . 3 year morbidity mortality rate 5 . Arterial de-stiffening , reduction central aortic blood pressure subject receive EMPAGLIFLOZIN</brief_summary>
	<brief_title>Double Blind Placebo Study JARDIANCEÂ® ( Empagliflozin ) Prehypertensives Type II Diabetics</brief_title>
	<detailed_description>Study rationale : The majority patient diabetes high blood pressure optimal . More 30 % patient type II diabetes prehypertensives systolic blood pressure 130 140 mmHg . If drug diabetes impact blood pressure patient drug reduce cardiovascular risk beyond reduction glucose level . There evidence EMPAGLIFLOZIN reduce blood pressure level comprehensive study available . Timelines Study duration : Start date : 01-01-2016 End date : 01-01-2019 Clinical Study Report date : June 2018 Publication date : 2018 , 2018 , 2019,2020 Methodology : Inclusion criterion 1 . Age 45 60 year . 2 . All patient go give inform consent participate study . 3 . Patients receive antihypertensive diabetes treatment ( newly diagnose diabetic ) 4 . BP 130 140 mmHg systolic BP ( prehypertensives ) 5 . Type II diabetes ( HbA1c 7.0-8.0 ) Exclusion criterion Known oversensitiveness , chronic renal disease ( GFR &lt; 60 ml/min ) ESRD , heart respiratory failure , recent MI , shock pregnancy lactation . Study drug : Clinical examination 0,1,6,12,24,36 month . - Duration follow-up : 3 year - Collected data : Ambulatory blood pressure monitoring , 24h SBP DBP time 0,12 , 24 month . - BMI , waist/hip ratio time 0 , 12 , 24,36 month . - HbA1c , insulin time 0 , 1 , 6,12 , 24,36 month . - K , Na , Cr , BUN , Chol , Tg , HDL , LDL , ALT , AST time 0 , 1 , 6,12 , 24,36 month . Number patient : 1054 Sample size justification : The reduction mean 24h SBP expect 2.5 mmHg . Previous study group report 12-14mmHg SD 24h mean SBP . The sample size require two side 5 % significance level 90 % power 527 patient per drug arm . Statistics/Data Analysis Stata Estimated sample size two-sample comparison mean Test Ho : m1 = m2 , m1 mean population 1 m2 mean population 2 Assumptions : alpha = 0.0500 ( two-sided ) power = 0.9000 m1 = 130 m2 = 132.5 sd1 = 12 sd2 = 13 n2/n1 = 1.00 Estimated required sample size : n1 = 527 n2 = 527 Population : Diabetes , prehypertension , outpatient . I</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion 1 . Age 45 65 year . 2 . All patient go give inform consent participate study . 3 . Patients receive antihypertensive diabetes treatment ( newly diagnose diabetic ) 4 . BP 130 140 mmHg systolic BP ( prehypertensives ) 5 . Type II diabetes ( HbA1c 7.08.0 ) Exclusion criterion 1 . Known oversensitiveness 2. chronic renal disease ( GFR &lt; 60 ml/min ) ESRD 3. heart respiratory failure , recent MI , shock 4. pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hypertension type II diabetes</keyword>
	<keyword>Cardiovascular morbidity mortality</keyword>
</DOC>